This preprint is under consideration at BMC Infectious Diseases. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
miR-125b-5p is A Promising Novel Plasma Biomarker for Alveolar Echinococcosis in Patients from the Southern Province of Qinghai
Deping Cao
Guilin Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1973-8879
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Alveolar echinococcosis is an infectious zoonotic disease caused by Echinococcus multilocularis that is endemic to the vast pastoral areas of southern Qinghai province of China. Alveolar echinococcosis affects the human liver, and its clinical manifestations are similar to those of liver tumors. It is also called “worm cancer,” as it induces irreversible liver fibrosis and brain metastases. Alveolar echinococcosis is a serious threat to human health and is a burden to patients and economies. When detected and treated early, patients with alveolar echinococcosis have a strong chance of recovery. Therefore, it is imperative to identify early diagnostic biomarkers of the disease. MicroRNAs (miRNAs) are short, single-stranded, non-coding RNA molecules that play key roles in a wide range of biological processes, and have been recently implicated in tumorigenesis. However, little is known about the role of miRNAs in alveolar echinococcosis. We have previously reported differentially expressed miRNAs in the plasma of patients with alveolar echinococcosis and healthy individuals, using microarray assay chips.
Methods: We screened 10 differentially expressed miRNAs based on their fold change and the available literature. Additionally, quantitative polymerase chain reaction was used to verify their expression in the plasma of alveolar echinococcosis patients. We found that hsa-miR-125b-5p was upregulated in the plasma and the hepatic tissue samples of alveolar echinococcosis patients; therefore, its role as a diagnostic biomarker for alveolar echinococcosis was investigated. Accordingly, hsa-miR-125b-5p was upregulated in plasma and hepatic tissue samples obtained from alveolar echinococcosis patients. Receiver operating characteristic curves showed that hsa-miR-125b-5p was associated with an area under the curve of 99.8% and 98.9% in the plasma and hepatic tissues of alveolar echinococcosis patients, respectively. Transfection of an LV-hsa-miR-125b-5p-inhibitor reduced apoptosis of L-O2 hepatocytes in vitro (P < 0.05). Thus, hsa-miR-125b-5p may promote liver cell proliferation and inhibit liver cell apoptosis.
Conclusions: Taken together, hsa-miR-125b-5p may be a promising diagnostic biomarker for the early non-invasive diagnosis of alveolar echinococcosis. We plan to validate the expression of hsa-miR-125b-5p in the plasma of patients with cystic echinococcosis, alveolar echinococcosis, and other liver diseases to determine the potential of hsa-miR-125-5p as a differential biomarker in future studies.
Keywords
alveolar echinococcosis, diagnostic biomarker, hsa-miR-125b-5p, plasma, hepatic tissue samples
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Sep, 2020
No community comments so far
Reviewers invited
Invitations sent on 18 Sep, 2020
Editor assigned
On 17 Sep, 2020
Submission checks complete
On 16 Sep, 2020
Editor invited
On 15 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This preprint is under consideration at BMC Infectious Diseases. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
miR-125b-5p is A Promising Novel Plasma Biomarker for Alveolar Echinococcosis in Patients from the Southern Province of Qinghai
Deping Cao
Guilin Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1973-8879
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Sep, 2020
No community comments so far
Reviewers invited
Invitations sent on 18 Sep, 2020
Editor assigned
On 17 Sep, 2020
Submission checks complete
On 16 Sep, 2020
Editor invited
On 15 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Alveolar echinococcosis is an infectious zoonotic disease caused by Echinococcus multilocularis that is endemic to the vast pastoral areas of southern Qinghai province of China. Alveolar echinococcosis affects the human liver, and its clinical manifestations are similar to those of liver tumors. It is also called “worm cancer,” as it induces irreversible liver fibrosis and brain metastases. Alveolar echinococcosis is a serious threat to human health and is a burden to patients and economies. When detected and treated early, patients with alveolar echinococcosis have a strong chance of recovery. Therefore, it is imperative to identify early diagnostic biomarkers of the disease. MicroRNAs (miRNAs) are short, single-stranded, non-coding RNA molecules that play key roles in a wide range of biological processes, and have been recently implicated in tumorigenesis. However, little is known about the role of miRNAs in alveolar echinococcosis. We have previously reported differentially expressed miRNAs in the plasma of patients with alveolar echinococcosis and healthy individuals, using microarray assay chips.
Methods: We screened 10 differentially expressed miRNAs based on their fold change and the available literature. Additionally, quantitative polymerase chain reaction was used to verify their expression in the plasma of alveolar echinococcosis patients. We found that hsa-miR-125b-5p was upregulated in the plasma and the hepatic tissue samples of alveolar echinococcosis patients; therefore, its role as a diagnostic biomarker for alveolar echinococcosis was investigated. Accordingly, hsa-miR-125b-5p was upregulated in plasma and hepatic tissue samples obtained from alveolar echinococcosis patients. Receiver operating characteristic curves showed that hsa-miR-125b-5p was associated with an area under the curve of 99.8% and 98.9% in the plasma and hepatic tissues of alveolar echinococcosis patients, respectively. Transfection of an LV-hsa-miR-125b-5p-inhibitor reduced apoptosis of L-O2 hepatocytes in vitro (P < 0.05). Thus, hsa-miR-125b-5p may promote liver cell proliferation and inhibit liver cell apoptosis.
Conclusions: Taken together, hsa-miR-125b-5p may be a promising diagnostic biomarker for the early non-invasive diagnosis of alveolar echinococcosis. We plan to validate the expression of hsa-miR-125b-5p in the plasma of patients with cystic echinococcosis, alveolar echinococcosis, and other liver diseases to determine the potential of hsa-miR-125-5p as a differential biomarker in future studies.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5